Advanced search
Publication Cover
Leukemia & Lymphoma Volume 62, 2021 - Issue 13
Submit an article Journal homepage
459
Views
4
CrossRef citations to date
0
Altmetric
Original Articles

Health disparities experienced by Black and Hispanic Americans with multiple myeloma in the United States: a population-based study

Samer Al Hadidia Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children’s Hospital and Houston Methodist Hospital, Houston, TX, USA;b Department of Medicine, Hematology and Oncology Section, Baylor College of Medicine, Houston, TX, USA;c Center of Excellence in Health Equity, Training and Research, Baylor College of Medicine, Houston, TX, USA;d Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA;e Myeloma Section, Winthrop P. Rockefeller Cancer Institute at the University of Arkansas for Medical Sciences, Little Rock, AR, USACorrespondence[email protected]
View further author information
,
Deepa Dongarwarc Center of Excellence in Health Equity, Training and Research, Baylor College of Medicine, Houston, TX, USAView further author information
,
Hamisu M. Salihuc Center of Excellence in Health Equity, Training and Research, Baylor College of Medicine, Houston, TX, USAView further author information
,
Rammurti T. Kamblea Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children’s Hospital and Houston Methodist Hospital, Houston, TX, USA;b Department of Medicine, Hematology and Oncology Section, Baylor College of Medicine, Houston, TX, USA;d Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USAView further author information
,
Premal Lullaa Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children’s Hospital and Houston Methodist Hospital, Houston, TX, USA;b Department of Medicine, Hematology and Oncology Section, Baylor College of Medicine, Houston, TX, USA;d Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USAView further author information
,
LaQuisa C. Hilla Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children’s Hospital and Houston Methodist Hospital, Houston, TX, USA;b Department of Medicine, Hematology and Oncology Section, Baylor College of Medicine, Houston, TX, USA;d Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USAView further author information
,
George Carruma Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children’s Hospital and Houston Methodist Hospital, Houston, TX, USA;b Department of Medicine, Hematology and Oncology Section, Baylor College of Medicine, Houston, TX, USA;d Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USAView further author information
,
Carlos A. Ramosa Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children’s Hospital and Houston Methodist Hospital, Houston, TX, USA;b Department of Medicine, Hematology and Oncology Section, Baylor College of Medicine, Houston, TX, USA;d Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USAView further author information
,
Helen E. Heslopa Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children’s Hospital and Houston Methodist Hospital, Houston, TX, USA;b Department of Medicine, Hematology and Oncology Section, Baylor College of Medicine, Houston, TX, USA;d Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USAView further author information
&
Saad Z. Usmanif Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Atrium Health, Charlotte, NC, USAView further author information
 show all
Pages 3256-3263 | Received 29 Apr 2021, Accepted 29 Jun 2021, Published online: 18 Jul 2021

References

  • DeSantis CE, Miller KD, Goding Sauer A, et al. Cancer statistics for African Americans, 2019. CA Cancer J Clin. 2019;69(3):211–233.
  • Rajkumar SV, Kumar S. Multiple myeloma current treatment algorithms. Blood Cancer J. 2020;10(9):94.
  • Ailawadhi S, Frank RD, Advani P, et al. Racial disparity in utilization of therapeutic modalities among multiple myeloma patients: a SEER-Medicare analysis. Cancer Med. 2017;6(12):2876–2885.
  • Costa LJ, Huang JX, Hari PN. Disparities in utilization of autologous hematopoietic cell transplantation for treatment of multiple myeloma. Biol Blood Marrow Transplant. 2015;21(4):701–706.
  • Samala RV, Valent J, Noche N, et al. Palliative care in patients with multiple myeloma. J Pain Symptom Manage. 2019;58(6):1113–1118.
  • Al Hadidi S, Mims M, Miller-Chism CN, et al. Participation of African American persons in clinical trials supporting U.S. Food and Drug Administration approval of cancer drugs. Ann Intern Med. 2020;173(4):320–322.
  • Al-Hamadani M, Hashmi SK, Go RS. Use of autologous hematopoietic cell transplantation as initial therapy in multiple myeloma and the impact of socio-geo-demographic factors in the era of novel agents. Am J Hematol. 2014;89(8):825–830.
  • Bhatnagar V, Gormley N, Kazandjian D, et al. FDA analysis of racial demographics in multiple myeloma trials. Blood. 2017;130(Suppl. 1):4352.
  • Ailawadhi S, Parikh K, Abouzaid S, et al. Racial disparities in treatment patterns and outcomes among patients with multiple myeloma: a SEER-Medicare analysis. Blood Adv. 2019;3(20):2986–2994.
  • HCUP NIS Database Documentation. Healthcare cost and utilization project (HCUP); 2021. Rockville (MD): Agency for Healthcare Research and Quality. Available from: www.hcup-us.ahrq.gov/db/nation/nis/nisdbdocumentation.jsp
  • Elixhauser A, Steiner C, Harris DR, et al. Comorbidity measures for use with administrative data. Med Care. 1998;36:8–27.
  • National Cancer Institute. Joinpoint regression program, version 4.2.0.2, statistical methodology and applications branch, surveillance research program; 2021; [cited 2021 Mar 11]. Available from: http://surveillance.cancer.gov/joinpoint/
  • Perrot A, Lauwers-Cances V, Cazaubiel T, et al. Early versus late autologous stem cell transplant in newly diagnosed multiple myeloma: long-term follow-up analysis of the IFM 2009 trial [abstract #143]. Blood (ASH Annual Meeting Abstracts); 2020. p. 136.
  • Dingli D, Ailawadhi S, Bergsagel PL, et al. Therapy for relapsed multiple myeloma: guidelines from the Mayo stratification for myeloma and risk-adapted therapy. Mayo Clin Proc. 2017;92(4):578–598.
  • Attal M, Lauwers-Cances V, Hulin C, et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med. 2017;376(14):1311–1320.
  • Auner HW, Pavlu J, Szydlo R, et al. Autologous haematopoietic stem cell transplantation in multiple myeloma patients from ethnic minority groups in an equal access healthcare system. Br J Haematol. 2012;157(1):125–127.
  • Manojlovic Z, Christofferson A, Liang WS, et al. Comprehensive molecular profiling of 718 multiple myelomas reveals significant differences in mutation frequencies between African and European descent cases. PLoS Genet. 2017;13(11):e1007087.
  • Ailawadhi S, Jacobus S, Sexton R, et al. Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the cooperative group clinical trials. Blood Cancer J. 2018;8(7):67.
  • Pulte ED, Nie L, Gormley N, et al. Survival of ethnic and racial minority patients with multiple myeloma treated with newer medications. Blood Adv. 2018;2(2):116–119.
  • Fillmore NR, Yellapragada SV, Ifeorah C, et al. With equal access, African American patients have superior survival compared to white patients with multiple myeloma: a VA study. Blood. 2019;133(24):2615–2618.
  • Porta-Sales J, Guerrero-Torrelles M, Moreno-Alonso D, et al. Is early palliative care feasible in patients with multiple myeloma? J Pain Symptom Manage. 2017;54(5):692–700.
  • Baughn LB, Pearce K, Larson D, et al. Differences in genomic abnormalities among African individuals with monoclonal gammopathies using calculated ancestry. Blood Cancer J. 2018;8:96–106.
  • Munjuluri A, Fillmore N, Cirstea D, et al. With equal access, African Americans with non-del17p multiple myeloma have superior overall survival, but del17p still carries poor prognosis across race: a VA study. Blood. 2019;134(Suppl. 1):4388.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.